TITLE

Addition of oral anticoagulation to antiplatelet therapy did not reduce CVD events in peripheral arterial disease

PUB. DATE
November 2007
SOURCE
ACP Journal Club;Nov/Dec2007, Vol. 147 Issue 3, p60
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article offers information on a study, investigating whether the combined use of oral anticoagulants and antiplatelet therapy in cardiovascular disease (CVD) events, in patients with peripheral arterial disease, is better than the antiplatelet therapy used alone. It describes the setting and the procedure in which the study is conducted. It reveals that the combination of oral anticoagulation and antiplatelet therapy was not more effective than antiplatelet therapy alone.
ACCESSION #
28019859

 

Related Articles

  • How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. McBane, Robert; Wysokinski, Waldemar; Schaefer, Jordan; Schaefer, Jordan K; McBane, Robert D; Wysokinski, Waldemar E // Annals of Hematology;Feb2016, Vol. 95 Issue 3, p437 

    The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety for stroke prevention in NVAF patients...

  • The Effects of Dabigatran on Select Specialty Coagulation Assays. Adcock, Dorothy M.; Gosselin, Robert; Kitchen, Steve; Dwyre, Denis M. // American Journal of Clinical Pathology;Jan2013, Vol. 139 Issue 1, p102 

    Dabigatran etexilate is a new oral anticoagulant that functions as a direct thrombin inhibitor. An inhibitor of thrombin has the potential to interfere with essentially all clot-based coagulation assays and select chromogenic assays, whereas the drug would not be expected to interfere in...

  • Treating Clotting Disorders: A Balance between Preventing Clots and Bleeding.  // Women's Health Advisor;Feb2013, Vol. 17 Issue 2, p3 

    The article focuses on positive and negative effect of anticoagulant drugs on human body. It informs about a study on warfarin, an anticoagulant drug that shows bleeding rates from the drug are higher than in clinical trials, and often are fatal depending on the amount of dose of drug that a...

  • Measuring Direct Thrombin Inhibitors With Routine and Dedicated Coagulation Assays. Curvers, Joyce; Van de Kerkhof, Daan; Stroobants, An K.; Van Den Dool, Erik-Jan; Scharnhorst, Volkher // American Journal of Clinical Pathology;Oct2012, Vol. 138 Issue 4, p551 

    The use of direct thrombin inhibitors (DTIs) for prophylactic or therapeutic anticoagulation is increasing because of the predictable bioavailability and short half-life of these DTIs. However, in certain situations, indication of the concentration is warranted. We investigated the effects of 3...

  • Cancer and thrombosis: an increasingly important association. Korte, Wolfgang // Supportive Care in Cancer;Mar2008, Vol. 16 Issue 3, p223 

    Introduction The association of cancer and venous thromboembolism (VTE) becomes increasingly important. VTE has been recognised as an increasingly frequent complication in cancer care. Furthermore, recent clinical trials have shown that therapy and prophylaxis of VTEs with low-molecular weight...

  • Are pharmacological properties of anticoagulants reflected in pharmaceutical pricing and reimbursement policy? Out-patient treatment of venous thromboembolism and utilization of anticoagulants in Poland. BOCHENEK, T.; CZARNOGORSKI, M.; NIZANKOWSKI, R.; PILC, A. // European Review for Medical & Pharmacological Sciences;Jun2014 Supplement, Vol. 18, p1649 

    OBJECTIVES: Pharmacotherapy with vitamin K antagonists (VKA) and low-molecular-weight heparins (LMWH) is a major cost driver in the treatment of venous thromboembolism (VTE). Major representatives of anticoagulants in Europe include: acenocoumarol and warfarin (VKA), enoxaparin, dalteparin,...

  • State Of The Art In Left Atrial Appendage Ligation - The Lariat. Janga, Pramod; Pamulapati, Hema; Kanmanthareddy, Arun; Vallakati, Ajay; Gunda, Sampath; Bommana, Sudharani; Jaeger, Misty; Reddy, Yeruva Madhu; Lakkireddy, Dhanunjaya // JAFIB: Journal of Atrial Fibrillation;Jun/Jul2014, Vol. 7 Issue 1, p49 

    Percutaneous left atrial appendage ligation (LAA) techniques have come to the forefront of management of atrial fibrillation (AF) patients who are at high risk of stroke and are unsuitable for oral anticoagulation therapy. LARIAT is a novel percutaneous endo-epicardial ligation technique for LAA...

  • Dietary vitamin K intake and stability of anticoagulation with coumarins; evidence derived from a clinical trial. Zuchinali, P.; Souza, G. C.; de Assis, M. C. S.; Rabelo, E. R.; Rohde, L. E. // Nutricion Hospitalaria;nov/dec2012, Vol. 27 Issue 6, p1987 

    Background: Dietary vitamin K intake has been considered a major factor that influences stability of oral anticoagulation (OA) with coumarins. Few studies have evaluated the relationship between amounts of dietary vitamin K intake and stability of anticoagulation. Objective: To assess whether...

  • RIVAROXABAN ASSAY: A SINGLE CENTRE EXPERIENCE MEASURING RIVAROXABAN LEVELS WITH A SPECIFIC ANTI XA ASSAY AND THE EFFECT ON THE STANDARD COAGULATION SCREEN. Niblock, A.; Murray, P.; Kearney, A. M.; Benson, G. // Ulster Medical Journal;Sep2015, Vol. 84 Issue 3, p190 

    The article presents the result of a study which assessed the therapeutic effect of rivaroxaban in patients undergoing blood coagulation screen in Northern Ireland. The variables considered include a comparison of rivaroxaban with vitamin K antagonists (VKA), the level of rivaroxaban...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics